SCHEMBL3433127

SCHEMBL3433127

CON(C)S(=O)(=O)c1ccc(Cn2nc(C(=O)Nc3nc4ccccc4s3)c3ccccc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.47
MAPT P10636 5/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
NPSR1 Q6W5P4 1/20 0.47
LMNA P02545 6/20 0.46
MAPK1 P28482 2/20 0.46
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
KDM4E B2RXH2 3/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
PRNP P04156 1/20 0.43
PTBP1 P26599 1/20 0.43
TSHR P16473 1/20 0.43
PTGER4 P35408 1/20 0.42
MCL1 Q07820 1/20 0.42
AKR1B1 P15121 1/20 0.42
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3430813 0.89 MAPT (0.51) HTTMAPTMEN1KMT2ANPSR1
SCHEMBL3755581 0.84 KMT2A (0.47) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL3432609 0.81 NPC1 (0.47) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL3430598 0.75 LRRK2 (0.53) SMN1; SMN2KDM4ENPC1RAB9ATSHR
SCHEMBL3428278 0.71 NPC1 (0.55) HTTMAPTMEN1KMT2ALMNA
SCHEMBL3429672 0.71 ATR (0.50) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL3755332 0.70 KDM4E (0.54) MEN1KMT2AMAPK1KDM4EPTGER4
SCHEMBL3432034 0.70 KMT2A (0.51) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL3427856 0.70 PTGER4 (0.48) MAPTMEN1KMT2AALDH1A1PTGER4
SCHEMBL3428395 0.69 PTGER4 (0.54) MEN1KMT2AKDM4EPTGER4MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US claimed
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 HTT 1560/4885MAPT 3715/4885MEN1 3958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.